Clinical Trials Logo

High Risk Non-Hodgkin's Lymphoma clinical trials

View clinical trials related to High Risk Non-Hodgkin's Lymphoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT00994643 Completed - Clinical trials for High Risk Non-Hodgkin's Lymphoma

Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma

Start date: February 5, 2009
Phase: Phase 2
Study type: Interventional

This is a study to see if maintenance therapy with low dose interleukin-2 (IL-2) and rituximab can delay or prevent recurrences in patients with high risk Non-Hodgkin's Lymphoma (NHL). IL-2 is a naturally occurring cytokine in our immune system which may enhance the activity of a known therapeutic agent rituximab, a monoclonal antibody against CD-20, in the setting of NHL.